![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Caption: Andrea Richardson, M.D., Ph.D, and her colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: DNA marker predicts platinum drug response in breast, ovarian cancer
|